Rothschild & Co Redburn Upgrades Novozymes A/S (OTCMKTS:NVZMY) to Strong-Buy

Key Points

• Rothschild & Co Redburn upgraded Novozymes A/S (NVZMY) to a "strong-buy" in a note to investors, signaling increased analyst enthusiasm for the stock.
• Novozymes missed the latest quarter's expectations, reporting EPS of $0.35 versus a $0.79 consensus and revenue of $1.18 billion versus $1.22 billion, with a net margin of 13.96% and return on equity of 6.37%.
• The company trades with a market capitalization of $24.45 billion, a P/E of 42.13 and P/E/G of 1.05, a 12‑month range of $49.90–$75.99, and low leverage (debt-to-equity 0.12).

Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) was upgraded by Rothschild & Co Redburn to a "strong-buy" rating in a note issued to investors on Friday,Zacks.com reports.

Novozymes A/S Stock Performance

Shares of NVZMY stock opened at $58.98 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 0.72 and a quick ratio of 1.00. The company's fifty day moving average price is $59.32 and its two-hundred day moving average price is $61.44. The firm has a market capitalization of $24.45 billion, a P/E ratio of 42.13, a P/E/G ratio of 1.05 and a beta of 1.11. Novozymes A/S has a 12 month low of $49.90 and a 12 month high of $75.99.

Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $0.35 earnings per share for the quarter, missing the consensus estimate of $0.79 by ($0.44). Novozymes A/S had a net margin of 13.96% and a return on equity of 6.37%. The business had revenue of $1.18 billion for the quarter, compared to analyst estimates of $1.22 billion. On average, research analysts anticipate that Novozymes A/S will post 1.82 earnings per share for the current fiscal year.

Novozymes A/S Company Profile

Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.

The company's product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.